Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Marc Lippman Biography and Net Worth

Director of Seagen

Dr. Lippman has served on the board of Seagen since June 2000. His extensive experience in patient care and oncology research brings a critical perspective to our development of targeted oncology therapies.

Dr. Lippman is a Professor of Oncology at Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center. Previously, he was the Kathleen and Stanley Glaser Professor of Medicine and Chairman of the Department of Medicine at the University of Miami Leonard M. Miller School of Medicine and the Deputy Director of the Sylvester Comprehensive Cancer Center. He has authored more than 400 peer-reviewed publications and one of the standard texts on breast cancer.

Dr. Lippman holds an M.D. from Yale, where he was elected to Alpha Omega Alpha, and a B.A. from Cornell University, where he graduated magna cum laude.

How do I contact Marc E. Lippman?: The corporate mailing address for Lippman and other Seagen executives is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. Seagen can also be reached via phone at (425) 527-4000 and via email at [email protected]. Learn More on Marc E. Lippman's contact information.
Has Marc E. Lippman been buying or selling shares of Seagen?: Marc E. Lippman has not been actively trading shares of Seagen over the course of the past ninety days. Learn More on Marc E. Lippman's trading history.
Who are Seagen's active insiders?: Seagen's insider roster includes Roger Dansey (Insider), David Epstein (CEO), David Gryska (Director), Vaughn Himes (Insider), Marc Lippman (Director), Jean Liu (EVP), Charles Romp (EVP), Clay Siegall (CEO), Todd Simpson (CFO), and Daniel Welch (Director). Learn More on Seagen's active insiders.

Marc E. Lippman Insider Trading History at Seagen

Marc E. Lippman Buying and Selling Activity at Seagen

Seagen Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Today's Range

Now: $228.74

$228.74

50 Day Range

MA: $228.74

$228.74

2 Week Range

Now: $228.74

$123.77

$228.96

Volume

86 shs

Average Volume

1,478,439 shs

Market Capitalization

$42.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.